Anti-CD38 Quadruplet Induction Regimens in TE NDMM: New Standard of Care

Opinion
Video

Panelists discuss how while daratumumab-based quadruplet regimens are increasingly becoming the standard of care for patients with transplant-eligible newly diagnosed multiple myeloma (TE NDMM) due to superior efficacy data, certain factors like frailty, comorbidities, and cost considerations may still warrant triplet therapy in select cases.

Recent Videos
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
4 experts in this video
4 experts in this video
2 experts in this video
Related Content